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ProteomicsParkinson's disease (PD) is the most common neurodegenerative movement disorder caused primarily by
selective degeneration of the dopaminergic neurons in substantia nigra. In this work the proteomes extracted
from primary ﬁbroblasts of two unrelated, hereditary cases of PD patients, with different parkin mutations,
were compared with the proteomes extracted from commercial adult normal human dermal ﬁbroblasts
(NHDF) and primary ﬁbroblasts from the healthy mother of one of the two patients. The results show that the
ﬁbroblasts from the two different cases of parkin-mutant patients display analogous alterations in the expression
level of proteins involved in different cellular functions, like cytoskeleton structure–dynamics, calcium homeo-
stasis, oxidative stress response, protein and RNA processing.
© 2015 Published by Elsevier B.V.1. Introduction
Parkinson's disease (PD) is the most frequent ageing-progressive,
neurodegenerative movement disorder starting by a selective loss of
dopaminergic neurons in the substantia nigra (SN) pars compacta,
caused by pathogenetic processes non-completely unveiled yet. It is
generally conceived that PD results from a complex interplay between
environmental and genetic factors, involving dysfunction in different
midbrain dopaminergic neurons, as well as other neuronal populations
in the central and peripheral nervous systems.
90% of PD cases are sporadic, 10% represent rare Mendelian heredi-
tary forms, caused by a variety of autosomal mutations in more than
10 PARK genes [1,2]. Mutations in mitochondrial DNA have also beennormal adult human dermal
ss Fingerprint; ROS, reactive
ranes and Bioenergetics (IBBE),
edical Sciences, Neurosciences
zianamaria.cocco@uniba.itfound to contribute to PD development and clinical course [3]. Elucida-
tion of the pathogenetic mechanism of familial cases, besides being
strategic in designing predictive and therapeutic measures for these
cases, can provide clues in identifying susceptible sites and networks,
whose acquired alterations might be involved/responsible for develop-
ment and progress in the life-course of sporadic PD.
More than 100 different pathogenetic mutations have so far been
identiﬁed in the parkin (PARK2) gene, encoding parkin, which belongs
to the ring between ring ﬁngers (RBR) class of E3 ubiquitin ligases [4,
5]. It is believed that loss of the ubiquitin ligase activity in the parkin
mutants impairs degradation by the ubiquitin–proteasome system of
speciﬁc substrates with accumulation of non-ubiquitinated toxic
products leading to neurodegeneration [6,7]. However, it should be
noted that there are more than 600 E3 ligases in the human genome,
13 belonging to the RBR family, which could compensate for the loss
of the parkin ligase activity [8,9].
On the other hand, investigations on transgenic animal models [10,
11] and parkin transfected cell cultures [12,13] have provided evidence
that parkin could also up- or down-regulate the expression of a number
of different genes, directly or as a consequence of its E3 ligase activity.
In the present work, a differential proteomic approach has been ap-
plied to characterize the protein expression proﬁle of primary ﬁbroblast
Table 1
Proteins differentially expressed in PD ﬁbroblasts, as identiﬁed by Peptide Mass Fingerprinting (PMF) strategy.
Proteins are listed according to their functional categories. Protein spot match identiﬁcation numbers (ID) are also reported.
IDa Protein name Accession number Gene name M.W. (Da)b
Theoretical
M.W. (kDa)c
Experimental
pId
Theoretical
pIe
Experimental
Mascot score Matched peptides Coverage Fold changef
P1 P2
Cytoskeleton structural proteins
1 7 Collagen, type I, alpha 1 (CO1A1) gi|22328092 COL1A1 139,952 139.4 5.70 5.70 549 49/64 48 +2.0⁎ +4.1⁎
2 8 Collagen, type I, alpha 1 (CO1A1) gi|22328092 COL1A1 139,952 138.8 5.70 5.73 298 46/83 50 +2.5⁎ +7.1⁎
Intermediated ﬁlament proteins
3 204 Vimentin (VIME) gi|62414289 VIM 53,676 41.43 5.06 4.85 238 21/40 51 −2.9⁎ −2.5⁎
4 205 Vimentin (VIME) gi|62414289 VIM 53,676 41.01 5.06 4.88 294 25/40 60 −3.7⁎ −2.7⁎
5 218 Vimentin (VIME) gi|62414289 VIM 53,676 39.00 5.06 4.81 345 28/40 62 −4.1⁎ −2.7⁎
6 220 Vimentin (VIME) gi|62414289 VIM 53,676 39.47 5.06 7.77 278 25/50 58 −2.8⁎ −2.5
7 233 Vimentin (VIME) gi|62414289 VIM 53,676 37.31 5.06 4.70 204 20/50 48 −4.3⁎ −3.1⁎
8 234 Vimentin (VIME) gi|62414289 VIM 53,676 37.61 5.06 4.67 275 23/40 56 −2.2⁎ −2.2⁎
Microﬁlament proteins
9 223 Actin, beta (ACTB) gi|14250401 ACTB 41,321 36.27 5.56 5.23 139 12/40 48 +2.1⁎ +1.9⁎
10 242 Actin, beta (ACTB) gi|14250401 ACTB 41,321 36.49 5.56 5.33 246 19/40 53 +2.4⁎ +2.3⁎
11 243 Actin, beta (ACTB) gi|14250401 ACTB 41,321 36.12 5.56 5.15 137 12/40 46 +4.0⁎ +3.8⁎
12 280 Beta tropomyosin (TPM2) gi|6573280 TPM2 29,980 30.79 4.70 4.60 339 29/40 77 +4.5⁎ +7.0⁎
13 291 Tropomyosin alpha-1 chain isoform X10 (TPM1) gi|530406402 TPM1 32,552 30.37 4.69 4.67 263 24/40 58 +5.0⁎ +6.8⁎
14 295 Tropomyosin alpha-1 chain isoform 5 (TPM1) gi|27597085 TPM1 32,846 30.10 4.69 4.66 179 19/40 58 +3.1⁎ +4.6⁎
15 301 Tropomyosin alpha-3 chain isoform 2 (TPM3) gi|24119203 TPM3 29,243 28.92 4.75 4.69 261 23/40 77 +2.0⁎ +2.1⁎
16 302 Tropomyosin alpha-4 chain isoform 2 (TPM4) gi|10441386 TPM4 27,570 28.66 4.77 4.62 263 23/40 57 +2.5⁎ +3.3⁎
Actin binding proteins
17 70 Caldesmon isoform 2 (CALD1) gi|4826657 CALD1 62,683 74.90 6.18 6.14 214 24/37 47 +2.0⁎ +2.2⁎
18 69 Caldesmon isoform 5 (CALD1) gi|15149465 CALD1 61,233 74.60 6.40 6.06 210 24/70 50 +2.6⁎ +2.9⁎
19 332 Caldesmon isoform 5 (CALD1) gi|15149465 CALD1 61,233 75.50 6.40 6.27 247 28/40 50 +2.8⁎ +3.2⁎
20 359 Caldesmon isoform 5 (CALD1) gi|15149465 CALD1 61,233 75.50 6.40 6.03 311 34/86 48 +2.1⁎ +2.2⁎
21 114 T-plastin polypeptide (PLST) gi|190028 PLS3 64,281 62.28 5.73 5.45 188 18/42 35 +2.1⁎ +2.2⁎
22 118 Plastin-3 isoform 2 (PLST) gi|288915539 PLS3 68,070 61.83 5.45 5.71 221 19/32 31 +3.4⁎ +3.0⁎
23 250 Moesin (MOES) gi|4505257 MSN 67,892 35.98 6.08 5.75 199 24/42 35 −3.0⁎ −2.2⁎
(continued on next page)
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Table 1 (continued)
IDa Protein name Accession number Gene name M.W. (Da)b
Theoretical
M.W. (kDa)c
Experimental
pId
Theoretical
pIe
Experimental
Mascot score Matched peptides Coverage Fold changef
P1 P2
Stress response related proteins
24 35 Heat shock protein gp96 precursor (ENPL) gi|15010550 HSP90B1 90,309 91.41 4.73 4.80 23 29/38 45 +3.6⁎ +3.3⁎
25 95 Heat shock cognate 71 kDa protein isoform 1 (HSP7C) gi|5729877 HSPA8 71,082 65.12 5.37 5.33 18 30/44 50 +1.9⁎ +2.1⁎
26 78 78 kDa glucose-regulated protein (GRP78) gi|386758 HSPA5 72,185 68.09 5.03 4.99 71 34/42 57 −2.3⁎ −2.1⁎
27 264 Heat shock protein gp96 precursor (ENPL) gi|15010550 HSP90B1 90,309 33.46 4.73 4.87 08 18/40 22 −5.2⁎ −4.2⁎
28 319 Heat shock protein beta-1 (HSPB1) gi|4504517 HSPB1 22,826 25.59 5.98 5.70 38 11/40 61 +2.5⁎ +2.8⁎
Calcium related proteins
29 110 Annexin A6 isoform X2 (ANXA6) gi|530380520 ANXA6 75,571 64.02 5.46 5.56 05 32/44 50 +1.4 +2.7⁎
30 154 Calreticulin (CALR) gi|4757900 CALR 48,283 47.98 4.29 4.40 92 24/50 66 −2.2⁎ −1.9⁎
31 256 Reticulocalbin-3 (RCN3) gi|28626510 RCN3 37,470 35.12 4.74 4.63 48 16/37 50 +1.8 +2.0⁎
32 297 Annexin A5 (ANXA5) gi|4502107 ANXA5 35,971 30.00 4.94 4.90 73 15/40 47 −1.9⁎ −2.3⁎
33 327 Protein S100-A4 (S10A4) gi|4506765 S100A4 11,949 12.00 5.85 5.60 19 8/16 46 −2.7⁎ −8.7⁎
34 328 Protein S100-A6 (S10A6) gi|7657532 S100A6 10,230 10.95 5.33 5.06 04 6/14 57 −2.4⁎ −3.0⁎
35 494 Protein S100-A10 (S10AA) gi|4506761 S100A10 11,310 12.00 6.82 6.92 92 13/39 67 −2.3⁎ −6.3⁎
Redox balance related proteins
36 324 Superoxide dismutase Cu–Zn (SODC) gi|7546430 SOD1 15,999 18.05 5.56 5.78 42 11/34 56 −1.9⁎ −2.1⁎
37 330 SH3 domain-binding glutamic acid-rich-like protein 3 (SH3L3) gi|13775198 SH3BGRL3 10,488 11.00 4.82 4.68 25 6/9 49 +2.2 +2.4⁎
38 338 Peroxiredoxin-4 (PRDX4) gi|5453549 PRDX4 30,749 25.66 5.86 5.75 67 10/16 50 −2.8⁎ −2.5⁎
Protein processing related proteins
39 19 Neutral alpha-glucosidase AB isoform 2 (GANAB) gi|38202257 GANAB 107,263 110.2 5.74 5.88 83 41/55 45 +1.8 +1.4⁎
40 119 Peptidyl-prolyl cis–trans isomerase FKBP9 isoform 1 (FKBP9) gi|33469985 FKBP9 63,500 62.67 4.91 4.85 84 21/36 28 +2.5⁎ +2.1⁎
41 489 Peptidyl-prolyl cis–trans isomerase A (PPIA) gi|10863927 PPIA 18,229 16.30 7.68 7.00 22 20/39 73 −1.7⁎ −1.4
42 45 Transitional endoplasmic reticulum ATPase (TERA) gi|6005942 VCP 89,950 87.49 5.14 5.20 24 56/103 50 +2.9⁎ +4.6⁎
RNA processing related proteins
43 72 Glycyl-tRNA synthetase (SYG) gi|600727 GARS 78,166 70.00 5.88 6.00 95 26/41 44 +2.4⁎ +2.4⁎
44 213 Ribonuclease/angiogenin inhibitor 1 isoform CRA_a (RINI) gi|119622735 RNH1 51,209 40.11 4.74 4.65 24 18/40 53 −7.8⁎ −4.2⁎
a ID spot identiﬁcation number that represents the protein spot of the 2-DE gels shown in Fig. 1.
b Theoretical molecular weight (Da).
c Experimental molecular weight (kDa).
d Theoretical isoelectric point.
e Experimental isoelectric point.
f Fold change in the protein expression level is calculated, for up-regulated protein, as the ratio between the normalized mean volume of each protein spot in the 2-DE map atient's ﬁbroblasts, P1 and P2 respectively and the combined nor-
malizedmean volume of that protein spot in the 2-DEmaps of the NHDF and C1 ﬁbroblasts. For down-regulated proteins the negative reciprocal value of this ratio is reported. O ots showing a volume fold change ≥1.7 and a p value b0.0167 (by
Bonferroni post-hoc test) are considered as containing up- or down-regulated proteins. Formore details seeMaterials andmethods. Fold change values for proteins contained in 110, 256, 330 and19 in P1 and spot ID 220 and 489 in P2were not
statistically signiﬁcant.
⁎ p b 0.0167.
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1963R. Lippolis et al. / Biochimica et Biophysica Acta 1852 (2015) 1960–1970cultures obtained from skin biopsies of two unrelated patients affected
by early-onset, autosomal recessive PD. These patients bore two
different compound-heterozygous mutations of parkin, resulting in the
absence of the full length 50 kDa parkin protein [14,15].
Parkin is expressed in human skin ﬁbroblasts [14–18] and their
primary cultures can be easily obtained from skin biopsies. These
cultures represent an ideal model for proteomic analysis of “living
cells” [19], to investigate the impact of parkin deletion on the expression
pattern of cellular proteins, in the various stages of the disease.
In this study we show that primary ﬁbroblasts of two unrelated,
different cases of parkin-mutant patients, display analogous alterations
in the expression level of proteins involved in different cellular
functions, like cytoskeleton structure–dynamics, calcium homeostasis,
oxidative stress response protein and RNA processing.2. Materials and methods
2.1. Skin ﬁbroblasts and culture conditions
Primary skin ﬁbroblasts from two unrelated patients affected by an
early-onset PD with different parkin compound heterozygous
mutations (P1 with del exon2–3/del exon3 [14], and P2 with del
exon7–9/Glu409X [15]) and from a healthy subject, displaying the
heterozygous del exon2–3, (P1's mother, 59 years old, related control,
C1) [14,15], were obtained by explants from skin punch biopsy, after
informed consent. The biopsies were taken in parallel, processed
simultaneously to establish primary cell lines. The P1 patient was a
35 year old woman with a positive familiar history of PD (one sister
and one brother) and an age at disease onset of 31 years. Clinical
response to dopaminergic treatment was moderate. The P2 patient
was a 48 year old woman with a positive familiar history of PD (one
sister and one brother) and an age at disease onset of 31 years. Clinical
response to dopaminergic treatment was good. Adult normal human
dermal ﬁbroblasts (NHDF), from a 56 years old subject, purchased from
Lonza Walkersville Inc (Walkersville, MD, USA), were also utilized as
unrelated control.
Cells were grown in high-glucose Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 10% (v/v) foetal bovine serum
(FBS), 1% (v/v) L-glutamine, 1% (v/v) penicillin/streptomycin, at 37 °C
in a humidiﬁed atmosphere of 5% CO2. All experiments were performed
on cells with similar passage numbers, ranging from 5 to 14, to avoid
artefacts due to senescence, known to occur at passage numbers greater
than 30. In the passage range used, ﬁbroblasts were β-Gal negative [20].
Each ﬁbroblast sample (NHDF, C1, P1 and P2 ﬁbroblasts) was cultured
in triplicate. Cells from each biological repeat, i.e., resulting from
the three independent cell cultures, were used for protein sample
preparation.PH 4
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Fig. 1. Representative 2-DE maps (linear IPG 4–7 pH) of the total protein extracts from norma
from the two unrelated PD patients (P1, P2). Protein spots showing different relative volumes i
and listed in Table 1.2.2. Two-dimensional gel electrophoresis (2DE)
The ﬁbroblast cultures from the two controls (C samples) and the two
PD patients (PD samples), at 80% of conﬂuence were collected by
trypsinization and centrifugation (1min at 4000 g and 25 °C) and imme-
diately frozen in liquid nitrogen. Cells were thawed on ice and suspended
in a lysis buffer containing 7 M urea, 2 M thiourea, 4% (w/v) 3-[(3-
cholamidopropyl) dimethylammonium]-1-propanesulfonate (CHAPS),
50 mM 1,4-dithio-DL-threitol (DTT), 4 mM phenylmethanesulfonyl
ﬂuoride (PMSF) and5% IPGbuffer (GEHealthcare, AmershamBiosciences
AB, Uppsala, Sweden). Unbroken cells were removed by centrifugation
(5 min at 10,000 g and 4 °C).
Protein concentration of ﬁbroblast lysates was determined using the
Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA),
according to themanufacturer's instruction, and bovine serum albumin
as a standard. The extracted proteins were stored at−80 °C until use.
Proteins were separated by 2-DE [21,22], according tomanufacturer
instructions (GE Healthcare). 250 μg of proteins solubilized in IPG
strip rehydration buffer (8 M urea, 2% (w/v) CHAPS, 0.5% IPG buffer,
2% (w/v) DTT and trace of bromo-phenol-blue), were loaded on
24-cm IPG strips (GE Healthcare) that provided linear pH gradients
3–10 and 4–7. The ﬁrst pH gradient is suited for an overview pattern
of total cell extracts, the second one is used to zoom the speciﬁc region
of the gel. Isoelectric focusing was carried out at 20 °C, using the Ettan
IPG-Phore Isoelectric Focusing System (GE Healthcare) to 69.5 kVh
totally. After focusing, the IPG strips were equilibrated for 12 min in
the equilibration buffer (50 mM Tris/HCl pH 8.8, 6 M urea, 30% (v/v)
glycerol, 2% (w/v) sodium dodecyl sulphate (SDS)) containing 1% DTT
and for 10 min in the same equilibration buffer containing 2.5%
iodoacetamide and 0.05% bromophenol blue. For the second dimension,
homogeneous SDS-12.5% polyacrylamide electrophoresis gels were
used. Electrophoresis was carried out in a Laemmli system [23] at
15 mA per gel constant current at 10 °C.
Molecular mass markers and pI standards were from Bio-Rad. The
gels were stained using Coomassie Blue Colloidal dye (Sigma-Aldrich,
St. Louis, MO, USA), which enabled quantiﬁcation of protein staining
intensities, allowing quantitative comparison of protein expression
levels between the samples. Protein extracts from each biological repeat
of control and PD samples were run in triplicate.
2.3. Image analysis
Coomassie stained gel imageswere acquired using an Image Scanner
(GE Healthcare) and analysed with ImageMaster 2D Platinum V.6
software (GE Healthcare). Spot detection was carried out using the
optimal values for spot intensity, spot area and saliency determined
by applying real time ﬁlters in order to minimise detection of artefacts
and to maximise real spots detection. To verify the auto-detected-7 
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l adult human dermal ﬁbroblasts (NHDF), healthy subject ﬁbroblasts (C1) and ﬁbroblasts
n the PD samples compared to the two control samples, are indicated by match ID number
1964 R. Lippolis et al. / Biochimica et Biophysica Acta 1852 (2015) 1960–1970results, manual spot editing was carried out for each image. Editing
consisted of deleting spots at the gel periphery and artifactual material
that escaped the ﬁltering process. Each ﬁbroblast sample (NHDF, C1,
P1, P2) was cultured in triplicate (biological replicates) and each
biological replicate was subjected to three 2DE. No signiﬁcant pattern
difference was found in the three 2DE gels of each ﬁbroblast culture
sample. In the second step, three gels for each ﬁbroblast sample (one
from each biological replicate) were used to create the four match setsA
Fig. 2. An illustrative example of spots containing proteins differentially expressed in PD ﬁbrob
relative spot volumes ± SD. Panel A: cytoskeleton structural proteins. Panel B: proteins relatedsubjected to image analysis (Fig. 1S). Reproducible landmarks were
used tomatch spots. Relative spot volume (% vol.), i.e., digitised staining
intensity integrated over the area of each individual spot divided by the
sumof volume of all spots in the gel andmultiplied by 100, was used for
spot quantiﬁcation [24]. Spots present in the three gels of the two
control samples and in the three gels of the two patient samples,
exhibiting a statistical signiﬁcant difference in their relative spot volume
(fold change ≥ 1.7; p value b0.05, two-tailed Student's t test) werelasts with respect to control samples and the relative graph displaying the mean values of
to stress response, calcium, redox balance and protein processing.
BFig. 2 (continued).
1965R. Lippolis et al. / Biochimica et Biophysica Acta 1852 (2015) 1960–1970
1966 R. Lippolis et al. / Biochimica et Biophysica Acta 1852 (2015) 1960–1970considered to contain differentially expressed proteins and were sub-
mitted to further mass spectrometric analysis. For these proteins the
mean volumes of each spot in the P1 (n = 3) and P2 (n = 3) samples
were independently compared to the combined mean volumes of the
corresponding spots of NHDF and C1 samples (n = 6) for calculating
the fold change in their relative spot volume (Table 1). Statistical com-
parison among the 3 groups (Controls (NHDF + C1), P1, P2) for each
protein exhibiting a signiﬁcant difference in their relative spot volume
(fold change ≥1.7) was performed using one-way analysis of variance
(ANOVA) for multiple groups followed by Bonferroni post-hoc test to
evaluate differences among groups; a p value b0.0167was set for statis-
tically signiﬁcant differences (Table 1). The match ID number was used
to identify all spots in a match.
2.4. Protein identiﬁcation by Peptide Mass Fingerprint (PMF) strategy
Spots of interest were excised from the 2-DE gels and in-gel tryptic
digestion was carried out following the procedure described by
Shevchenko [25].
Peptide mixtures were analysed using a matrix assisted laser
desorption ionization-time of ﬂight-mass spectrometry (MALDI-TOF-
MS) instrument (M@LDI, Waters, Milford, MA, USA) operating in
positive-ion reﬂectron mode. The instrument was externally calibrated
using signals generated by a peptidemixture of angiotensin (20 fmol/μL,
m/z 931.5154), angiotensin II (100 fmol/μL, m/z 1046.5423), ACTH
fragment 18–39 (125 fmol/μL, m/z 2465.1989), and insulin oxidized B
chain (100 fmol/μL, m/z 3494.6513). Mass spectra, acquired in the m/z
range 750–3500, were internally re-calibrated by considering the signal
generated by ACTH as lockmass, and processed usingMassLynx 2.1 and
ProteinLynx Global Server software 2.1 (Waters). Peak lists weremanu-
ally inspected. Protein identiﬁcationwas achieved by using peak lists for
database searches against the NCBInr database by means of the Mascot
software (http://www.matrixscience.com/) [26]. Parameters for all
searches were as follows: all entries as taxonomic category, trypsin as
enzyme, carbamidomethyl as ﬁxed modiﬁcation for cysteine residues,
up to one missing cleavage and up to 50 ppm as mass tolerance. The
protein identiﬁcation was accepted only when the obtained Mascot
score was well above the threshold indicated by the software as
signiﬁcant (Mascot score threshold indicates that the probability that
the observed match is a random event is minor than 5%). Identiﬁed
proteins were classiﬁed on the basis of their biological and molecular
functions using the bioinformatics resource Gene Ontology (GO, www.
geneontology.org)
3. Results
3.1. 2-DE-PAGE and data analysis
Differential analysis of the overall intracellular proteome of primary
skin ﬁbroblast of two unrelated patients, bearing two different parkin
compound heterozygous mutations (P1 and P2), was performed.
Commercial adult normal human dermal ﬁbroblasts (NHDF) and skin
primary ﬁbroblasts from a healthy subject (C1), P1's mother, were
used as control samples. We have used the primary ﬁbroblasts of a
family member as they can represent an optimal control since should
differ from the disease's ﬁbroblasts only in themutated gene of interest,
while having the same genetic background. The 2-DE protein analysis of
the ﬁbroblast lysates was performed in the pH ranges 3–10 and 4–7. In
Fig. 1 the representative 2-DE gels of the four samples, in the pH range
4–7, are shown.
Proteomic maps of control samples and PD samples showed several
hundreds of well-resolved protein spots distributed over a wide range
of pI values and molecular masses. The overall position and the number
of protein spots observed was similar in the 2-DEmaps of the two con-
trol samples (476±24 and 458±32 in NHDF and C1, respectively) andof the two PD samples (459 ± 37 and 448 ± 43 in P1 and P2,
respectively).
The percent of matches between gels from the same class and from
the four different classes was similar (around 68%) without statistically
signiﬁcant differences between the classes. To reduce the possibility of
false positives, only the protein spots systematically present in all gels
of each class were considered in the analysis.
Several protein spots with masses ranging from 140 to 10 kDa and
pIs ranging from 4.4 to 6.92 were found to have signiﬁcantly different
relative volumes in the PD samples as compared to control samples.
3.2. Proteins identiﬁcation
Spots of interest were excised from the gels and proteins contained
in these spots were identiﬁed by the PMF strategy. The identiﬁcation
was further conﬁrmed by checking that the position of each spot in
the 2-DE map was in agreement with the expected molecular weight
and pI of the identiﬁed protein. Of these, 26 proteins were over-
expressed while 18 proteins were under-expressed (positive or
negative changes in their relative volume ≥ 1.7 fold) as listed in
Table 1 and shown in Fig. 1 (see also Table 1S in Supplementary
Material). Illustrative examples of changes in relative volume of some
spots and the graph displaying the statistical analysis are shown in
Fig. 2.
The identiﬁed proteins could be classiﬁed in the following groups:
i) Cytoskeleton structural proteins: collagen type I alpha 1 (CO1A1,
spot ID 7 and 8), three isoforms of actin beta (ACTB, spot ID 223,
242 and 243), beta tropomyosin (TPM2, spot ID 280), tropomyo-
sin alpha-1 chain isoform X10 and isoform 5 (TPM1, spot ID 291,
295), tropomyosin alpha-3 chain isoform 2 (TPM3, spot ID 301)
and tropomyosin alpha-4 chain isoform 2 (TPM4, spot ID 302).
All these proteins, which are microﬁlament components, were
over-expressed in the PD samples. Actin-binding proteins:
caldesmon isoform 5 (CALD1, spot ID 69, 332 and 359),
caldesmon isoform 2 (CALD1 spot ID 70), T-plastin (PLST spot
ID 114) and plastin-3 isoform 2 (PLST, spot ID 118) were also
over-expressed in PD samples. Conversely, a moesin fragment
(MOES, spot ID 250) and six vimentin isoforms (VIME spots ID
204, 205, 218, 220, 233 and 234), components of intermediate
ﬁlaments, were under-expressed in PD samples.
(ii) Stress response related proteins: heat shock cognate 71 kDa
protein isoform 1 (HSP7C, spot ID 95) and heat shock protein
beta-1 (HSPB1, spot ID 319) were over-expressed, whereas
78 kDa glucose-regulated protein (GRP78, spot ID 78) was
under-expressed in PD samples. Heat shock protein gp96
(ENPL) was present in spot ID 35 (over-expressed) and ID 264
(under-expressed). It is worth to note that the position of spot
ID 35 in the 2-DE map was coherent with the pI and molecular
mass of the identiﬁed protein, while, on the contrary, spot ID
264 was located in a region of the 2-DE map where smaller
proteins migrated (about 35 kDa). In agreement with this
ﬁnding, data from protein identiﬁcation showed that spot ID
264 actually contained a C-terminal fragment of ENPL, probably
originated from a proteolytic processing event of this protein.
Recently this protein was shown to undergo calpain-dependent
proteolytic cleavage during etoposide-induced apoptosis [27].
(iii) Calcium related proteins: annexin A5 (ANXA5, spot ID 297),
three proteins belonging to the S100 family, namely S100A4,
S100A6 and S100A10 (S10A4, S10A6, S10AA, spot ID 327, 328,
and 494) and calreticulin (CALR, spot ID154) were under-
expressed in PD samples. Annexin A6 isoform X2 (ANXA6, spot
ID 110) and reticulocalbin-3 (RCN3, spot ID 256) were signiﬁ-
cantly over-expressed only in P2 cells.
(iv) Redox balance related proteins: Superoxide dismutase Cu–Zn
(SODC, spot ID 324) and peroxiredoxin-4 (PRDX4 spot ID 338)
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acid-rich-like protein 3 (SH3L3, spot ID 330) was signiﬁcantly
over-expressed only in P2 samples.
(v) Protein processing related proteins: peptidyl-prolyl cis–trans
isomerase FKBP9, isoform 1 (FKBP9, spot ID 119) and transla-
tional endoplasmic reticulum ATPase (TERA, spot ID 45) resulted
signiﬁcantly over-expressed in PD ﬁbroblasts.
(vi) RNA processing related proteins: glycyl-tRNA synthetase (SYG,
spot ID 72) was over-expressed in PD ﬁbroblasts while
ribonuclease/angiogenin inhibitor 1, isoform CRA_a (RINI, spot
ID 213) was markedly under-expressed in PD samples.4. Discussion
The present proteomic study shows that two unrelated cases of PD
patients (P1 and P2) with different pathogenetic compound heterozy-
gous PARK2 mutations (del exon2–3/del exon3 in P1 and del
exon7–9/Glu409X in P2), both resulting in parkin loss in the primary
skin ﬁbroblasts, present analogous alterations in the expression level
of proteins pertaining to different cellular processes. Extension of the
proteomic analysis to ﬁbroblasts from more cases of PD patients with
mutations in PARK2 or in other PARK genes and comparison of the
results with proteomic data obtained from brain tissue of sporadic PD
patients [28–32], can contribute to shed light on the pathogenetic
mechanism of PD and identify speciﬁc biomarkers for predictive and
therapeutic intervention.
How parkin deletion could modulate the expression level of diverse
categories of proteins and how possible interactions of the affected pro-
teins could contribute to the pathogenesis of PD are open questions. It is
generally believed that the loss of the E3 ligase activity of parkin impairs
degradation of altered, unwanted protein species by the proteasome
system [7]. It is conceivable that parkin, in addition to proteasomal
degradation, modulates, directly or by ubiquitination, factors that
control the expression of different proteins at transcriptional and/or
translational level [12,13]. Clearly, the present results motivate more
work on the cellular impact of parkin pathogenetic mutations.
Among the different proteinswhose levelswere found to be affected
by the parkinmutations,we discuss here possible functional implication
of proteins showing signiﬁcant, around 2 fold, expression changes in the
ﬁbroblasts of the two cases of parkin-mutant PD (Table 1).
Several proteins differentially expressed in the PD ﬁbroblasts are
cytoskeleton structural proteins related to intermediate ﬁlaments,
microﬁlaments and actin binding proteins. These proteins play a critical
role inmaintaining cell shape,motility [33–35] andneuron–glia interac-
tion [36,37].
It has been reported that several cytoskeleton proteins have altered
levels in neurodegenerative disorders [38–40]. A decreased level of six
vimentin isoforms was observed in the ﬁbroblasts from the two PD
patients. VIME is the major structural component of intermediate
ﬁlaments and contributes to cell–cell junctions such as desmosomes. It
maintains cell shape, cytoskeleton stabilization and spatial localization
of cell organelles [41]. Three isoforms of actin beta, components of the
cytoskeleton microﬁlament proteins, were over-expressed in PD
samples. It is worth nothing that an increased level of beta actin was
also found in the brain of neurotoxin 6-OHDA rat model of PD [42]. An
increased level of ﬁve isoforms of tropomyosin, components of actin
ﬁlaments [43], were found in both PD samples.
Isoforms of caldesmon, an actin binding protein, were over-
expressed in PD ﬁbroblasts. Caldesmon co-localizes with tropomyosin
on thin ﬁlaments in proximity to myosin thick ﬁlaments, binds and
stabilizes actin ﬁlaments, and regulates actin–myosin interaction in a
Ca2+/calmodulin and/or phosphorylation-dependent manner [44].
Likewise, we observed increased level of plastins. These proteins,
characterized by Ca2+ and actin-binding domains, are involved inactin bundling, assembly, turnover and stabilization. The different
expression level of the cytoskeleton structural proteins observed in
the ﬁbroblasts of both patients could be related to the molecular [35]
and ultrastructural alterations [14] observed in these cells, and under-
score the functional link between parkin and cytoskeleton. Proper
cytoskeleton dynamics is fundamental for efﬁcient regulation of
mitochondrial mobility, in response to neuronal activity in order to
meet increased metabolic requirements at sites distant from the cell
body [45].
Cytoskeleton remodelling has also been implicated in different
aspects of neuronal morphogenesis, such as growth, guidance,
branching, and stability of axons and dendrites. Both neuronal and as-
trocytic components are involved in adaptation to pathophysiological
processes affecting dopaminergic systems as indicated by the alteration
of functional plasticity of neuroglial interaction in toxin animalmodel of
PD [36]. This aspect is critical with respect to the functional involvement
of gap junction coupling and connexin expression in modulating
neurodegenerative or neuroprotective conditions [37].
Of relevant interest is the present ﬁnding of a general, signiﬁcant
decreased level in both patient ﬁbroblasts of calcium binding
proteins which buffer intracellular calcium concentration within
physiological concentration range, thus preventing Ca2+ excitotoxicity
[46,47].
The Ca2+-binding proteins found to be decreased in both PD
samples were: three S100 Ca2+-binding proteins (S100A-4, S100A-6,
S100-A10), a protein family involved in the modulations of different
cellular processes [48]; calreticulin, a chaperone protein located in the
ER lumen, involved in ER Ca2+ storage capacity [49], assembly, folding
and quality control of ER proteins [50]; annexin A5, which exhibits a
Ca2+-dependent binding to phospholipids and membranes and plays
a role in neuronal cell death [51,52]. Previous studies reported a
decrease in Annexin A5 concentration in cerebrospinal ﬂuid (CSF) of
PD patients [53].
The decreased cellular level of Ca2+ binding proteins in the primary
ﬁbroblasts of the two parkin-mutant patients lend support to the
emerging evidence that calcium deregulation has a major role in
Parkinson's disease [54,47]. It has been reported that parkin deﬁciency
in cellular model leads to an increase in the calcium level that makes
cells more vulnerable to neurotoxins [55].
Hurley et al. [47] found increased expression of Cav1.3 voltage-gated
calcium channel in the post-mortembrain of early stage Parkinson's dis-
ease patients together with a reduced level of Ca2+ binding proteins.
Both of these changes were proposed to contribute to enhanced cellular
Ca2+ concentration and consequent Ca2+ excitotoxicity. An increased
cytosolic concentration of Ca2+ (N10−5 M) results in a large
accumulation of Ca2+ in mitochondria [56] where it can induce a
sequential series of deleterious events including: opening of the
cyclosporine-sensitive permeability transition pore and loss of
cytochrome c and other pro-apoptotic factors from mitochondria
[57]. A previous work has shown in primary ﬁbroblasts of a patient
affected by familial parkinsonism associated with homozygous
PINK1 mutation, a loss of mitochondrial cytochrome c, which resulted
in the inhibition of mitochondrial respiratory activity, depression of
ATP production and increased mitochondrial reactive oxygen species
(ROS) production [58].
Our proteomic analysis showed in the two PD samples, altered
expression of stress response and redox balance related proteins
which exert a protective role against oxidative damage, protein
misfolding and inclusion body formation [59].
Some Heat Shock Proteins HSPs were up-regulated by two fold in
PD samples and these are: HSP gp96, which chaperones secreted
andmembrane proteins in the ER lumen [60], HSP7C, which ensures
the proper folding of nascent or misfolded proteins [61,62],
and HSPB1, which interacts with actin and intermediate ﬁlaments
[63]. Conversely, the 70-kDa-protein GRP78, member of HSP 70
family resulted to be under-expressed in PD ﬁbroblasts. The level
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[64–66].
Two proteins involved in the regulation of redox processes,
namely peroxiredoxin-4 and superoxide dismutase Cu–Zn, were
under-expressed. Peroxiredoxin-4 is an ER protein, member of the
peroxiredoxin (PRDXs) ubiquitous protein family that protects cells
from reactive oxygen species [67] Under-expression of peroxiredoxin-
4 and SODC could account for the increased level of H2O2 detected in
the ﬁbroblasts of these PD patients [14,15]. Furthermore, the proteomic
analysis led to identify some proteins differentially expressed in the PD
ﬁbroblasts involved in protein and RNA processing.
Two ER proteins: FKBP and TERA were over-expressed in PD
ﬁbroblasts. The FKBP protein family has a prolyl isomerase activity, is
enriched in the nervous systemandmay be involved in PDpathogenesis
[68]. TERA is an ER protein member of the AAA+ ATPase family with a
central role in protein folding, vesicle transport and fusion and ubiqui-
tin–proteasome and autophagy degradation pathways [69]. Our results
showed also an over-expression of glycyl-tRNA synthetase in PD
ﬁbroblasts. The activity of this enzyme is regulated by the aminoacyl-
tRNA synthetase cofactor p38 (AIMP2), a parkin substrate whose
up-regulation in parkin null mice induced apoptosis of neuronal cells
[70].
Ribonuclease/angiogenin inhibitor 1, isoform CRA (RINI) was under-
expressed in PD ﬁbroblasts. RNH1 is known to inhibit RNases such as
RNASE1, RNASE2 and angiogenin [71]. Its knockdown promotes
stress-induced translational silencing [72].
5. Conclusions
Parkin deletion in primaryﬁbroblasts from the two cases of unrelated,
autosomal recessive familial PD patients is shown to result in analogous
alterations in the expression level of proteins of different functional cate-
gories. These results indicate the complexity of cellular alterations caused
by parkin deletion and imply limitations of hypothesis-driven studies
concentrated only on a speciﬁc cellular function.
Many proteins whose expression was altered in PD samples were
cytoskeleton structural proteins. The modulation of vimentin
expression level, which resulted to be decreased, might have important
implications due to the role of this protein in cell architecture and be
indicative of a structural impairment of the cytoskeleton in PD cells [35].
Our present ﬁnding of a large decrease in the level of Ca2+-binding /
buffering proteins in the parkin-mutant ﬁbroblasts lend support to the
concept that Ca2+ excitotoxicity plays a central role in Parkinson's dis-
ease [46,47]. A historical cohort study in Denmark [73] has indicated
that treatment of patients with dihydropyridine Ca2+-channels
blockers, largely used in therapeutical treatment of hypertension, was
associated with a reduced risk of incident PD and reduced mortality
among patients. These observations warrant further basic and clinical
studies aimed to develop and test blockers of Ca2+ channels in the
prevention and treatment of Parkinson's disease.
Amain target of Ca2+ excitotoxicity is represented bymitochondria.
Large accumulation of Ca2+ in these organelles results in the deleterious
cascade of events discussed above, which ultimately causes impairment
of mitochondrial respiration and ATP production and enhancement of
ROS production, as observed in our previous work on the PD ﬁbroblasts
of the two patients examined here [14,15]. Impaired mitochondrial
energy metabolism, oxidative stress and age-related progressive
accumulation of oxidatively damaged and misfolded proteins, which
aggregate and impair cellular housekeeping and specialized functions,
contribute, all together, to the PD pathogenesis [74–76].
Recent studies on Parkin deﬁcient cells showed also an increased
vulnerability of the endoplasmic reticulum to oxidative stress [77],
representing an additional pathogenetic event in PD [78–81]. All this
supports an adjuvant therapeutic action of natural antioxidant
substances (see the case of resveratrol [15] and hydroxytyrosol [82])
that can promote the expression and/or the activity of gene products(so-called vitagens) involved in mitochondrial biogenesis and cell
protection against oxidative stress and production/accumulation of
damaged/misfolded proteins which ultimately result in neuron loss
[83–85].
Supplementary data to this article can be found online at http://dx.
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